Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026
April 04, 2023 07:30 ET
|
Small Pharma Inc.
LONDON, April 04, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted...
Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry
March 07, 2023 07:50 ET
|
Small Pharma Inc.
LONDON, March 07, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted...
Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results
March 07, 2023 07:30 ET
|
Small Pharma Inc.
-Patients’ self-reported depression and wellbeing scores corroborate MADRS efficacy data-Statistically significant improvement in anxiety symptoms offers potential in new indications beyond depression...
Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference
March 01, 2023 07:50 ET
|
Small Pharma Inc.
LONDON, March 01, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted...
First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
February 15, 2023 07:50 ET
|
Small Pharma Inc.
SPL028 is a proprietary deuterated DMT candidate with multi-layered IP protection Phase I study will compare two routes of SPL028 administration; intravenous and intramuscular LONDON, Feb. 15, 2023...
Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
February 01, 2023 07:50 ET
|
Small Pharma Inc.
New United States patents will provide further support for the Company’s proprietary position in a key jurisdiction United States grants will bring the Company’s total to 16 granted patents and over...
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
January 25, 2023 07:05 ET
|
Small Pharma Inc.
Positive top-line results from Phase IIa trial of SPL026 in Major Depressive Disorder New SPL026 trials underway and screening commenced in the first in-human study of SPL028 LONDON, Jan. 25,...
Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder
January 25, 2023 06:00 ET
|
Small Pharma Inc.
First placebo-controlled efficacy study completed to date exploring a short-duration psychedelic for depression demonstrates rapid and durable response Primary endpoint met with a statistically...
Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25
January 24, 2023 16:00 ET
|
Small Pharma Inc.
LONDON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted...
First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026
January 09, 2023 07:50 ET
|
Small Pharma Inc.
LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted...